1
|
Masjuan J, Gállego J, Aguilera J, Arenillas J, Castellanos M, Díaz F, Portilla J, Purroy F. Use of cardiovascular polypills for the secondary prevention of cerebrovascular disease. NEUROLOGÍA (ENGLISH EDITION) 2021. [DOI: 10.1016/j.nrleng.2017.10.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
2
|
Selak V, Webster R, Stepien S, Bullen C, Patel A, Thom S, Arroll B, Bots ML, Brown A, Crengle S, Dorairaj P, Elley CR, Grobbee DE, Harwood M, Hillis GS, Laba TL, Neal B, Peiris D, Rafter N, Reid C, Stanton A, Tonkin A, Usherwood T, Wadham A, Rodgers A. Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials. Heart 2018; 105:42-48. [DOI: 10.1136/heartjnl-2018-313108] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/03/2018] [Revised: 05/17/2018] [Accepted: 05/24/2018] [Indexed: 01/11/2023] Open
Abstract
ObjectiveThe aim of this study was to determine the effect of polypill-based care on the achievement of 2016 European Society of Cardiology (ESC) guideline targets for blood pressure (BP), low-density lipoprotein (LDL) cholesterol and antiplatelet therapy.MethodsWe conducted an individual participant data meta-analysis of three randomised clinical trials that compared a strategy using a polypill containing aspirin, statin and antihypertensive therapy with usual care in patients with a prior cardiovascular disease (CVD) event or who were at high risk of their first event. Overall, the trials included 3140 patients from Australia, England, India, Ireland, the Netherlands and New Zealand (75% male, mean age 62 years and 76% with a prior CVD event). The primary outcome for this study was the proportion of people achieving ESC guideline targets for BP, LDL and antiplatelet therapy.ResultsThose randomised to polypill-based care were more likely than those receiving usual care to achieve recommended targets for BP (62% vs 58%, risk ratio (RR) 1.08, 95% CI 1.02 to 1.15), LDL (39% vs 34%, RR 1.13, 95% CI 1.02 to 1.25) and all three targets for BP, LDL and adherence to antiplatelet therapy (the latter only applicable to those with a prior CVD event) simultaneously (24% vs 19%, RR 1.27, 95% CI 1.10 to 1.47) at 12 months. There was no difference between groups in antiplatelet adherence (96% vs 96%, RR 1.00, 95% CI 0.98 to 1.01). There was heterogeneity by baseline treatment intensity such that treatment effects increased with the fewer the number of treatments being taken at baseline: for patients taking 3, 2 and 0–1 treatment modalities the RRs for reaching all three guideline goals simultaneously were 1.10 (95% CI 0.94 to 1.30, 22% vs 20%), 1.62 (95% CI 1.09 to 2.42, 27% vs 17%) and 3.07 (95% CI 1.77 to 5.33, 35% vs 11%), respectively.ConclusionsPolypill-based therapy significantly improved the achievement of all three ESC targets for BP, LDL and antiplatelet therapy compared with usual care, particularly among those undertreated at baseline.
Collapse
|
3
|
Masjuan J, Gállego J, Aguilera JM, Arenillas JF, Castellanos M, Díaz F, Portilla JC, Purroy F. Use of cardiovascular polypills for the secondary prevention of cerebrovascular disease. Neurologia 2018; 36:1-8. [PMID: 29325730 DOI: 10.1016/j.nrl.2017.10.013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2017] [Revised: 09/28/2017] [Accepted: 10/03/2017] [Indexed: 12/30/2022] Open
Abstract
INTRODUCTION There is little control of cardiovascular (CV) risk factors in secondary prevention after an ischaemic stroke, in part due to a lack of adherence to treatment. The CV polypill may contribute to proper treatment adherence, which is necessary for CV disease prevention. This study aimed to establish how and in what cases the CV polypill should be administered. METHODS A group of 8 neurologists drafted consensus recommendations using structured brainstorming and based on their experience and a literature review. RESULTS These recommendations are based on the opinion of the participating experts. The use of the CV polypill is beneficial for patients, healthcare professionals, and the health system. Its use is most appropriate for atherothrombotic stroke, lacunar stroke, stroke associated with cognitive impairment, cryptogenic stroke with CV risk factors, and silent cerebrovascular disease. It is the preferred treatment in cases of suspected poor adherence, polymedicated patients, elderly people, patients with polyvascular disease or severe atherothrombosis, young patients in active work, and patients who express a preference for the CV polypill. Administration options include switching from individual drugs to the CV polypill, starting treatment with the CV polypill in the acute phase in particular cases, use in patients receiving another statin or an angiotensin ii receptor antagonist, or de novo use if there is suspicion of poor adherence. Nevertheless, use of the CV polypill requires follow-up on the achievement of the therapeutic objectives to make dose adjustments. CONCLUSIONS This document is the first to establish recommendations for the use of the CV polypill in cerebrovascular disease, beyond its advantages in terms of treatment adherence.
Collapse
Affiliation(s)
- J Masjuan
- Servicio de Neurología, Hospital Universitario Ramón y Cajal, Madrid, España; Departamento de Medicina, Facultad de Medicina, Universidad de Alcalá (IRYCIS), Invictus Plus, Red Nacional de Investigación en Ictus, Madrid, España.
| | - J Gállego
- Complejo Hospitalario de Navarra, Pamplona, España
| | - J M Aguilera
- Hospital Universitario de Nuestra Señora de Valme, Sevilla, España
| | - J F Arenillas
- Hospital Clínico Universitario de Valladolid, Valladolid, España
| | - M Castellanos
- Complexo Hospitalario Universitario A Coruña, Instituto de Investigación Biomédica de Coruña INIBIC, La Coruña, España
| | - F Díaz
- Hospital General Universitario Gregorio Marañón, Madrid, España
| | - J C Portilla
- Hospital Universitario San Pedro de Alcántara, Cáceres, España
| | - F Purroy
- Hospital Arnau de Vilanova, Lérida, España
| |
Collapse
|
4
|
Selak V, Webster R. Polypills for the secondary prevention of cardiovascular disease: effective in improving adherence but are they safe? Ther Adv Drug Saf 2017; 9:157-162. [PMID: 29387338 DOI: 10.1177/2042098617747836] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2017] [Accepted: 11/21/2017] [Indexed: 11/17/2022] Open
Abstract
International guidelines recommend blood pressure-lowering therapy, statins and aspirin for people who have had a cardiovascular event but use of these medications is low, particularly for lower income countries. Clinical trials have demonstrated that combining these medications into a single pill or capsule (a 'polypill') improves adherence, systolic blood pressure and low density lipoprotein cholesterol compared with usual care in secondary prevention. Uptake of polypill-based care has been underwhelming, possibly due to safety concerns. Overall, results from the clinical trials of polypill use among people who have had a cardiovascular event show no immediate safety concerns. Increased use and adherence to medications will always be associated with side effects however use within a combination medication has not been shown to be any less safe than individual component medications. Research investigating the relative consequences of nonadherence to a polypill compared with individual components would be useful.
Collapse
Affiliation(s)
| | - Ruth Webster
- The George Institute for Global Health, Level 5, 1 King Street, Newtown, New South Wales, 2042, Australia
| |
Collapse
|
5
|
Impact of switching to polypill based therapy by baseline potency of medication: Post-hoc analysis of the SPACE Collaboration dataset. Int J Cardiol 2017; 249:443-447. [DOI: 10.1016/j.ijcard.2017.09.162] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/26/2017] [Revised: 08/07/2017] [Accepted: 09/15/2017] [Indexed: 02/01/2023]
|
6
|
Webster R, Castellano JM, Onuma OK. Putting polypills into practice: challenges and lessons learned. Lancet 2017; 389:1066-1074. [PMID: 28290996 DOI: 10.1016/s0140-6736(17)30558-5] [Citation(s) in RCA: 65] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/18/2017] [Revised: 02/13/2017] [Accepted: 02/13/2017] [Indexed: 12/30/2022]
Abstract
Regulatory approvals for cardiovascular polypills are increasing rapidly across more than 30 countries. The evidence clearly shows polypills improve adherence and cardiovascular disease risk factors for patients with indications for use of polypill components-ie, those with established cardiovascular disease or at high risk. However, the implementation of polypills into clinical practice has many challenges. The clinical trials literature provides insights into the clinical impact of a polypill strategy, including cost-effectiveness, safety of use, substantial improvement in adherence, and better risk factor control than usual care. Despite the clear need for such a strategy and the available clinical data backing up the use of the polypill in different patient populations, challenges to widespread implementation, such as an absence of government reimbursement and poor physician uptake (identified from on the ground experience in countries following commercial rollout), have greatly obstructed real-world implementation. Obtaining the full public health benefit of polypills will require education, advocacy, endorsement, and implementation by key global agencies such as WHO and national clinical bodies, as well as endorsement from governments.
Collapse
Affiliation(s)
- Ruth Webster
- George Institute for Global Health, University of Sydney, Sydney, Australia.
| | - Jose M Castellano
- National Center for Cardiovascular Research, Carlos III Institute of Health, Madrid, Spain; Monteprincipe University Hospital, HM Group, Madrid, Spain; CEU San Pablo School of Medicine, San Pablo, Madrid, Spain
| | | |
Collapse
|
7
|
Bahiru E, de Cates AN, Farr MRB, Jarvis MC, Palla M, Rees K, Ebrahim S, Huffman MD. Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases. Cochrane Database Syst Rev 2017; 3:CD009868. [PMID: 28263370 PMCID: PMC6464321 DOI: 10.1002/14651858.cd009868.pub3] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
BACKGROUND Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death and disability worldwide, yet ASCVD risk factor control and secondary prevention rates remain low. A fixed-dose combination of blood pressure- and cholesterol-lowering and antiplatelet treatments into a single pill, or polypill, has been proposed as one strategy to reduce the global burden of ASCVD. OBJECTIVES To determine the effect of fixed-dose combination therapy on all-cause mortality, fatal and non-fatal ASCVD events, and adverse events. We also sought to determine the effect of fixed-dose combination therapy on blood pressure, lipids, adherence, discontinuation rates, health-related quality of life, and costs. SEARCH METHODS We updated our previous searches in September 2016 of CENTRAL, MEDLINE, Embase, ISI Web of Science, and DARE, HTA, and HEED. We also searched two clinical trials registers in September 2016. We used no language restrictions. SELECTION CRITERIA We included randomised controlled trials of a fixed-dose combination therapy including at least one blood pressure-lowering and one lipid-lowering component versus usual care, placebo, or an active drug comparator for any treatment duration in adults 18 years old or older, with no restrictions on presence or absence of pre-existing ASCVD. DATA COLLECTION AND ANALYSIS Three review authors independently selected studies for inclusion and extracted the data for this update. We evaluated risk of bias using the Cochrane 'Risk of bias' assessment tool. We calculated risk ratios (RR) for dichotomous data and mean differences (MD) for continuous data with 95% confidence intervals (CI) using fixed-effect models when heterogeneity was low (I2 < 50%) and random-effects models when heterogeneity was high (I2 ≥ 50%). We used the GRADE approach to evaluate the quality of evidence. MAIN RESULTS In the initial review, we identified nine randomised controlled trials with a total of 7047 participants and four additional trials (n = 2012 participants; mean age range 62 to 63 years; 30% to 37% women) were included in this update. Eight of the 13 trials evaluated the effects of fixed-dose combination (FDC) therapy in populations without prevalent ASCVD, and the median follow-up ranged from six weeks to 23 months. More recent trials were generally larger with longer follow-up and lower risk of bias. The main risk of bias was related to lack of blinding of participants and personnel, which was inherent to the intervention. Compared with the comparator groups (placebo, usual care, or active drug comparator), the effects of the fixed-dose combination treatment on mortality (FDC = 1.0% versus control = 1.0%, RR 1.10, 95% CI 0.64 to 1.89, I2 = 0%, 5 studies, N = 5300) and fatal and non-fatal ASCVD events (FDC = 4.7% versus control = 3.7%, RR 1.26, 95% CI 0.95 to 1.66, I2 = 0%, 6 studies, N = 4517) were uncertain (low-quality evidence). The low event rates for these outcomes and indirectness of evidence for comparing fixed-dose combination to usual care versus individual drugs suggest that these results should be viewed with caution. Adverse events were common in both the intervention (32%) and comparator (27%) groups, with participants randomised to fixed-dose combination therapy being 16% (RR 1.16, 95% CI 1.09 to 1.25, 11 studies, 6906 participants, moderate-quality evidence) more likely to report an adverse event . The mean differences in systolic blood pressure between the intervention and control arms was -6.34 mmHg (95% CI -9.03 to -3.64, 13 trials, 7638 participants, moderate-quality evidence). The mean differences (95% CI) in total and LDL cholesterol between the intervention and control arms were -0.61 mmol/L (95% CI -0.88 to -0.35, 11 trials, 6565 participants, low-quality evidence) and -0.70 mmol/L (95% CI -0.98 to -0.41, 12 trials, 7153 participants, moderate-quality evidence), respectively. There was a high degree of statistical heterogeneity in comparisons of blood pressure and lipids (I2 ≥ 80% for all) that could not be explained, so these results should be viewed with caution. Fixed-dose combination therapy improved adherence to a multidrug strategy by 44% (26% to 65%) compared with usual care (4 trials, 3835 participants, moderate-quality evidence). AUTHORS' CONCLUSIONS The effects of fixed-dose combination therapy on all-cause mortality or ASCVD events are uncertain. A limited number of trials reported these outcomes, and the included trials were primarily designed to observe changes in ASCVD risk factor levels rather than clinical events, which may partially explain the observed differences in risk factors that were not translated into differences in clinical outcomes among the included trials. Fixed-dose combination therapy is associated with modest increases in adverse events compared with placebo, active comparator, or usual care but may be associated with improved adherence to a multidrug regimen. Ongoing, longer-term trials of fixed-dose combination therapy will help demonstrate whether short-term changes in risk factors might be maintained and lead to expected differences in clinical events based on these changes.
Collapse
Affiliation(s)
- Ehete Bahiru
- Northwestern UniversityInternal Medicine; Division of Cardiology201 E. Huron St. Galter 19‐100ChicagoIllinoisUSA60611
| | - Angharad N de Cates
- Warwick Medical School, University of WarwickDivision of Health SciencesCoventryUKCV4 7AL
| | - Matthew RB Farr
- Warwick Medical School, University of WarwickDivision of Health SciencesCoventryUKCV4 7AL
| | - Morag C Jarvis
- Warwick Medical School, University of WarwickDivision of Health SciencesCoventryUKCV4 7AL
| | - Mohan Palla
- Wayne State UniversityDepartment of Medicine540 E Canfield StDetroitMichiganUSA48201
| | - Karen Rees
- Warwick Medical School, University of WarwickDivision of Health SciencesCoventryUKCV4 7AL
| | - Shah Ebrahim
- London School of Hygiene & Tropical MedicineDepartment of Non‐communicable Disease EpidemiologyKeppel StreetLondonUKWC1E 7HT
| | - Mark D Huffman
- Northwestern University Feinberg School of MedicineDepartments of Preventive Medicine and Medicine (Cardiology)680 N. Lake Shore Drive, Suite 1400ChicagoILUSA60611
| | | |
Collapse
|
8
|
Chow CK, Islam SMS, Farmer A, Bobrow K, Maddision R, Whittaker R, Dale LP, Lechner A, Niessen L, Lear SA, Eapen ZJ, Santo K, Stepien S, Redfern J, Rodgers A. Text2PreventCVD: protocol for a systematic review and individual participant data meta-analysis of text message-based interventions for the prevention of cardiovascular diseases. BMJ Open 2016; 6:e012723. [PMID: 27798018 PMCID: PMC5073594 DOI: 10.1136/bmjopen-2016-012723] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
INTRODUCTION Text message interventions have been shown to be effective in prevention and management of several non-communicable disease risk factors. However, the extent to which their effects might vary in different participants and settings is uncertain. We aim to conduct a systematic review and individual participant data (IPD) meta-analysis of randomised clinical trials examining text message interventions aimed to prevent cardiovascular diseases (CVD) through modification of cardiovascular risk factors (CVRFs). METHODS AND ANALYSIS Systematic review and IPD meta-analysis will be conducted according to Preferred Reporting Items for Systematic review and Meta-Analysis of IPD (PRISMA-IPD) guidelines. Electronic database of published studies (MEDLINE, EMBASE, PsycINFO and Cochrane Library) and international trial registries will be searched to identify relevant randomised clinical trials. Authors of studies meeting the inclusion criteria will be invited to join the IPD meta-analysis group and contribute study data to the common database. The primary outcome will be the difference between intervention and control groups in blood pressure at 6-month follow-up. Key secondary outcomes include effects on lipid parameters, body mass index, smoking levels and self-reported quality of life. If sufficient data is available, we will also analyse blood pressure and other secondary outcomes at 12 months. IPD meta-analysis will be performed using a one-step approach and modelling data simultaneously while accounting for the clustering of the participants within studies. This study will use the existing data to assess the effectiveness of text message-based interventions on CVRFs, the consistency of any effects by participant subgroups and across different healthcare settings. ETHICS AND DISSEMINATION Ethical approval was obtained for the individual studies by the trial investigators from relevant local ethics committees. This study will include anonymised data for secondary analysis and investigators will be asked to check that this is consistent with their existing approvals. Results will be disseminated via scientific forums including peer-reviewed publications and presentations at international conferences. TRIAL REGISTRATION NUMBER CRD42016033236.
Collapse
Affiliation(s)
- Clara K Chow
- The George Institute for Global Health, Sydney, Australia
- Sydney Medical School, University of Sydney, Sydney, Australia
| | - Sheikh Mohammed Shariful Islam
- The George Institute for Global Health, Sydney, Australia
- Sydney Medical School, University of Sydney, Sydney, Australia
- Ludwig-Maximillian Universitat, Munich, Germany
| | | | - Kirsty Bobrow
- Oxford University, Oxford, UK
- University of Cape Town, South Africa
| | - Ralph Maddision
- The University of Auckland, Auckland, New Zealand
- Deakin University, Melbourne, Australia
| | | | | | - Andreas Lechner
- Diabetes Research Group, Ludwig—Maximilians University, Munich, Germany
| | - Louis Niessen
- Liverpool School of Tropical Medicine, Liverpool, UK
- Johns Hopkins University, Baltimore, Maryland, USA
| | - Scott A Lear
- Simon Fraser University and St. Paul's Hospital, Vancouver, British Columbia, Canada
| | - Zubin J Eapen
- Duke Clinical Research Institute, Durham, North Carolina, USA
| | - Karla Santo
- The George Institute for Global Health, Sydney, Australia
- Sydney Medical School, University of Sydney, Sydney, Australia
| | | | - Julie Redfern
- The George Institute for Global Health, Sydney, Australia
- Sydney Medical School, University of Sydney, Sydney, Australia
| | - Anthony Rodgers
- The George Institute for Global Health, Sydney, Australia
- Sydney Medical School, University of Sydney, Sydney, Australia
| |
Collapse
|
9
|
Koh JS, Park Y, Tantry US, Ahn JH, Kang MG, Kim K, Jang JY, Park HW, Park JR, Hwang SJ, Kwak CH, Hwang JY, Gurbel PA, Jeong YH. Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents: The ACCEL-COMBO trial. Platelets 2016; 28:187-193. [PMID: 27560946 DOI: 10.1080/09537104.2016.1206197] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Dual antiplatelet therapy (DAPT) with clopidogrel and aspirin is a widely prescribed regimen to prevent ischemic events in patients undergoing percutaneous coronary intervention (PCI). A fixed-dose combination (FDC) capsule (HCP0911) has been developed to provide dosing convenience and improve adherence. We compared the antiplatelet effects of single daily dose HCP0911 with separate treatment with daily 75 mg clopidogrel plus 100 mg aspirin. This was a randomized, open-label, two-period, crossover, non-inferiority study conducted in stented patients who had been treated for at least 6 months with clopidogrel and aspirin. Thirty patients were randomly assigned to receive either daily 75 mg clopidogrel plus 100 mg aspirin treatment or HCP0911 for 2 weeks and then were crossed over to the other treatment for 2 weeks. Pharmacodynamic effects were measured with VerifyNow, light transmittance aggregometry (LTA), and thromboelastography (TEG®). The primary endpoint was P2Y12 Reaction Units (PRU) measured by VerifyNow. PRUs during treatment with HCP0911 were not inferior to those during separate treatment (202 ± 52 vs. 207 ± 60 PRU; mean difference, -5 PRU; 90% confidence interval of difference, -23 to 13 PRU; P for non-inferiority = 0.015 for predetermined limit). "BASE" and Aspirin Reaction Units by VerifyNow did not differ between the two treatments. During each treatment, there were no differences in maximal and final platelet aggregations by LTA (all P values ≥0.822) and TEG® measurements. In conclusion, in stented patients, the antiplatelet effect of a fixed-dose clopidogrel-aspirin combination, HCP0911, was not inferior to separate administration of clopidogrel and aspirin.
Collapse
Affiliation(s)
- Jin-Sin Koh
- a Department of Internal Medicine , Gyeongsang National University School of Medicine and Gyeongsang National University Hospital , Jinju , Republic of Korea
| | - Yongwhi Park
- b Department of Internal Medicine , Gyeongsang National University School of Medicine and Cardiovascular Center, Gyeongsang National University Changwon Hospital , Changwon , Republic of Korea
| | - Udaya S Tantry
- c Inova Center for Thrombosis Research and Drug Development, Inova Heart and Vascular Institute , Fairfax , VA , USA
| | - Jong-Hwa Ahn
- b Department of Internal Medicine , Gyeongsang National University School of Medicine and Cardiovascular Center, Gyeongsang National University Changwon Hospital , Changwon , Republic of Korea
| | - Min Gyu Kang
- a Department of Internal Medicine , Gyeongsang National University School of Medicine and Gyeongsang National University Hospital , Jinju , Republic of Korea
| | - Kyehwan Kim
- a Department of Internal Medicine , Gyeongsang National University School of Medicine and Gyeongsang National University Hospital , Jinju , Republic of Korea
| | - Jeong Yoon Jang
- b Department of Internal Medicine , Gyeongsang National University School of Medicine and Cardiovascular Center, Gyeongsang National University Changwon Hospital , Changwon , Republic of Korea
| | - Hyun Woong Park
- a Department of Internal Medicine , Gyeongsang National University School of Medicine and Gyeongsang National University Hospital , Jinju , Republic of Korea
| | - Jeong Rang Park
- a Department of Internal Medicine , Gyeongsang National University School of Medicine and Gyeongsang National University Hospital , Jinju , Republic of Korea
| | - Seok-Jae Hwang
- a Department of Internal Medicine , Gyeongsang National University School of Medicine and Gyeongsang National University Hospital , Jinju , Republic of Korea
| | - Choong Hwan Kwak
- b Department of Internal Medicine , Gyeongsang National University School of Medicine and Cardiovascular Center, Gyeongsang National University Changwon Hospital , Changwon , Republic of Korea
| | - Jin-Yong Hwang
- a Department of Internal Medicine , Gyeongsang National University School of Medicine and Gyeongsang National University Hospital , Jinju , Republic of Korea
| | - Paul A Gurbel
- c Inova Center for Thrombosis Research and Drug Development, Inova Heart and Vascular Institute , Fairfax , VA , USA
| | - Young-Hoon Jeong
- b Department of Internal Medicine , Gyeongsang National University School of Medicine and Cardiovascular Center, Gyeongsang National University Changwon Hospital , Changwon , Republic of Korea.,d Institute of the Health Sciences , Gyeongsang National University , Jinju , Republic of Korea
| |
Collapse
|
10
|
Selak V, Bullen C, Stepien S, Arroll B, Bots M, Bramley D, Cass A, Grobbee D, Hillis GS, Molanus B, Neal B, Patel A, Rafter N, Rodgers A, Thom S, Tonkin A, Usherwood T, Wadham A, Webster R. Do polypills lead to neglect of lifestyle risk factors? Findings from an individual participant data meta-analysis among 3140 patients at high risk of cardiovascular disease. Eur J Prev Cardiol 2016; 23:1393-400. [PMID: 26945024 DOI: 10.1177/2047487316638216] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/17/2015] [Accepted: 02/17/2016] [Indexed: 11/15/2022]
Abstract
AIM The aim of this study was to investigate whether polypill-based care for the prevention of cardiovascular disease (CVD) is associated with a change in lifestyle risk factors when compared with usual care, among patients with CVD or high calculated cardiovascular risk. METHODS We conducted an individual participant data meta-analysis of three trials including patients from Australia, England, India, Ireland, the Netherlands and New Zealand that compared a strategy using a polypill containing aspirin, statin and antihypertensive therapy with usual care in patients with a prior CVD event or who were at high risk of their first event. Analyses investigated any differential effect on anthropometric measures and self-reported lifestyle behaviours. RESULTS Among 3140 patients (75% male, mean age 62 years and 76% with a prior CVD event) there was no difference in lifestyle risk factors in those randomised to polypill-based care compared with usual care over a median of 15 months, either across all participants combined, or in a range of subgroups. Furthermore, narrow confidence intervals (CIs) excluded any major effect; for example differences between the groups in body mass index was -0.1 (95% CI -0.2 to 0.1) kg/m(2), in weekly duration of moderate intensity physical activity was -2 (-26 to 23) minutes and the proportion of smokers was 16% vs 17% (RR 0.98, 0.84 to 1.15) at the end of trial. DISCUSSION This analysis allays concern that polypill-based care may lead to neglect of lifestyle risk factors, at least among high-risk patients. Maximally effective preventive approaches should address lifestyle factors alongside pharmaceutical interventions, as recommended by major international guidelines.
Collapse
Affiliation(s)
- Vanessa Selak
- Department of Epidemiology and Biostatistics, University of Auckland, New Zealand
| | - Chris Bullen
- National Institute for Health Innovation, University of Auckland, New Zealand
| | - Sandrine Stepien
- The George Institute for Global Health, University of Sydney, Australia
| | - Bruce Arroll
- Department of General Practice and Primary Health Care, University of Auckland, New Zealand
| | - Michiel Bots
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, the Netherlands
| | | | - Alan Cass
- Menzies School of Health Research, Charles Darwin University, Australia
| | - Diederick Grobbee
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, the Netherlands
| | | | - Barbara Molanus
- South Australian Health and Medical Research Institute, Australia
| | - Bruce Neal
- The George Institute for Global Health, University of Sydney, Australia
| | - Anushka Patel
- The George Institute for Global Health, University of Sydney, Australia
| | - Natasha Rafter
- National Institute for Health Innovation, University of Auckland, New Zealand Department of Epidemiology and Public Health Medicine, Royal College of Surgeons in Ireland, Ireland
| | - Anthony Rodgers
- The George Institute for Global Health, University of Sydney, Australia
| | - Simon Thom
- International Centre for Circulatory Health, Imperial College London, UK
| | - Andrew Tonkin
- Department of Epidemiology and Preventive Medicine, Monash University, Australia
| | - Tim Usherwood
- Department of General Practice, University of Sydney Westmead, Australia
| | - Angela Wadham
- National Institute for Health Innovation, University of Auckland, New Zealand
| | - Ruth Webster
- The George Institute for Global Health, University of Sydney, Australia
| |
Collapse
|
11
|
Webster R, Patel A, Selak V, Billot L, Bots ML, Brown A, Bullen C, Cass A, Crengle S, Raina Elley C, Grobbee DE, Neal B, Peiris D, Poulter N, Prabhakaran D, Rafter N, Stanton A, Stepien S, Thom S, Usherwood T, Wadham A, Rodgers A. Effectiveness of fixed dose combination medication ('polypills') compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries. Int J Cardiol 2015; 205:147-156. [PMID: 26736090 DOI: 10.1016/j.ijcard.2015.12.015] [Citation(s) in RCA: 93] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/03/2015] [Revised: 11/26/2015] [Accepted: 12/12/2015] [Indexed: 11/25/2022]
Abstract
AIMS To conduct a prospective, individual participant data (IPD) meta-analysis of randomised controlled trials comparing a polypill-based approach with usual care in high risk individuals. METHODS AND RESULTS Three trials comparing polypill-based care with usual care in individuals with CVD or high calculated cardiovascular risk contributed IPD. Primary outcomes were self-reported adherence to combination therapy (anti-platelet, statin and ≥ two blood pressure (BP) lowering agents), and difference in mean systolic BP (SBP) and LDL-cholesterol at 12 months. Analyses used random effects models. Among 3140 patients from Australia, England, India, Ireland, New Zealand and The Netherlands (75% male, mean age 62 years), median follow-up was 15 months. At baseline, 84%, 87% and 61% respectively were taking a statin, anti-platelet agent and at least two BP lowering agents. At 12 months, compared to usual care, participants in the polypill arm had higher adherence to combination therapy (80% vs. 50%, RR 1.58; 95% CI, 1.32 to 1.90; p < 0.001), lower SBP (-2.5 mmHg; 95% CI, -4.5 to -0.4; p = 0.02) and lower LDL-cholesterol (-0.1 mmol/L; 95% CI, -0.2 to 0.0; p = 0.04). Baseline treatment levels were a major effect modifier for adherence and SBP (p-homog < 0.0001 and 0.02 respectively) with greatest improvements seen among those under-treated at baseline. CONCLUSIONS Polypill therapy significantly improved adherence, SBP and LDL-cholesterol in high risk patients compared with usual care, especially among those who were under-treated at baseline.
Collapse
Affiliation(s)
- Ruth Webster
- The George Institute for Global Health, University of Sydney, PO Box M201, Missenden Rd, Camperdown, NSW 2050, Australia.
| | - Anushka Patel
- The George Institute for Global Health, University of Sydney, PO Box M201, Missenden Rd, Camperdown, NSW 2050, Australia
| | - Vanessa Selak
- National Institute for Health Innovation, School of Population Health, The University of Auckland, Private Bag 92019, Auckland Mail Centre, Auckland 1142, New Zealand
| | - Laurent Billot
- The George Institute for Global Health, University of Sydney, PO Box M201, Missenden Rd, Camperdown, NSW 2050, Australia
| | - Michiel L Bots
- The Julius Center for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, The Netherlands
| | - Alex Brown
- South Australian Health and Medical Research Institute, PO Box 11060, Adelaide, SA 5001, Australia
| | - Chris Bullen
- National Institute for Health Innovation, School of Population Health, The University of Auckland, Private Bag 92019, Auckland Mail Centre, Auckland 1142, New Zealand
| | - Alan Cass
- Menzies School of Health Research, Charles Darwin University, PO Box 41096, Casuarina, NT 0811, Australia
| | - Sue Crengle
- Invercargill Medical Centre, 160 Don St, Invercargill 9810, New Zealand
| | - C Raina Elley
- Department of General Practice and Primary Health Care, The University of Auckland, Auckland, New Zealand
| | - Diederick E Grobbee
- The Julius Center for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, The Netherlands
| | - Bruce Neal
- The George Institute for Global Health, University of Sydney, PO Box M201, Missenden Rd, Camperdown, NSW 2050, Australia
| | - David Peiris
- The George Institute for Global Health, University of Sydney, PO Box M201, Missenden Rd, Camperdown, NSW 2050, Australia
| | - Neil Poulter
- Imperial College, 59/61 North Wharf Road, St Mary's Campus, London, United Kingdom
| | - Dorairaj Prabhakaran
- Centre for Chronic Disease Control, 4th Floor, Plot no. 47, Sector 44, Near Metro Huda City Center, Gurgaon, Haryana 122002, India
| | - Natasha Rafter
- National Institute for Health Innovation, School of Population Health, The University of Auckland, Private Bag 92019, Auckland Mail Centre, Auckland 1142, New Zealand
| | - Alice Stanton
- Royal College of Surgeons in Ireland, 123 St Stephens Green, Dublin 2, Ireland
| | - Sandrine Stepien
- The George Institute for Global Health, University of Sydney, PO Box M201, Missenden Rd, Camperdown, NSW 2050, Australia
| | - Simon Thom
- Imperial College, 59/61 North Wharf Road, St Mary's Campus, London, United Kingdom
| | - Tim Usherwood
- Sydney Medical School - Westmead, University of Sydney, Sydney, Australia
| | - Angela Wadham
- National Institute for Health Innovation, School of Population Health, The University of Auckland, Private Bag 92019, Auckland Mail Centre, Auckland 1142, New Zealand
| | - Anthony Rodgers
- The George Institute for Global Health, University of Sydney, PO Box M201, Missenden Rd, Camperdown, NSW 2050, Australia
| | | |
Collapse
|
12
|
Bovet P, Chiolero A, Paccaud F, Banatvala N. Screening for cardiovascular disease risk and subsequent management in low and middle income countries: challenges and opportunities. Public Health Rev 2015; 36:13. [PMID: 29450041 PMCID: PMC5804497 DOI: 10.1186/s40985-015-0013-0] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2015] [Accepted: 11/18/2015] [Indexed: 11/30/2022] Open
Abstract
Background Cardiovascular disease (CVD), mainly heart attack and stroke, is the leading cause of premature mortality in low and middle income countries (LMICs). Identifying and managing individuals at high risk of CVD is an important strategy to prevent and control CVD, in addition to multisectoral population-based interventions to reduce CVD risk factors in the entire population. Methods We describe key public health considerations in identifying and managing individuals at high risk of CVD in LMICs. Results A main objective of any strategy to identify individuals at high CVD risk is to maximize the number of CVD events averted while minimizing the numbers of individuals needing treatment. Scores estimating the total risk of CVD (e.g. ten-year risk of fatal and non-fatal CVD) are available for LMICs, and are based on the main CVD risk factors (history of CVD, age, sex, tobacco use, blood pressure, blood cholesterol and diabetes status). Opportunistic screening of CVD risk factors enables identification of persons with high CVD risk, but this strategy can be widely applied in low resource settings only if cost effective interventions are used (e.g. the WHO Package of Essential NCD interventions for primary health care in low resource settings package) and if treatment (generally for years) can be sustained, including continued availability of affordable medications and funding mechanisms that allow people to purchase medications without impoverishing them (e.g. universal access to health care). This also emphasises the need to re-orient health systems in LMICs towards chronic diseases management. Conclusion The large burden of CVD in LMICs and the fact that persons with high CVD can be identified and managed along cost-effective interventions mean that health systems need to be structured in a way that encourages patient registration, opportunistic screening of CVD risk factors, efficient procedures for the management of chronic conditions (e.g. task sharing) and provision of affordable treatment for those with high CVD risk. The focus needs to be in primary care because that is where most of the population can access health care and because CVD programmes can be run effectively at this level.
Collapse
Affiliation(s)
- Pascal Bovet
- 1Institute of Social and Preventive Medicine (IUMSP), University Hospital Centre, Rue de la Corniche 10, 2013 Lausanne, Switzerland
| | - Arnaud Chiolero
- 1Institute of Social and Preventive Medicine (IUMSP), University Hospital Centre, Rue de la Corniche 10, 2013 Lausanne, Switzerland
| | - Fred Paccaud
- 1Institute of Social and Preventive Medicine (IUMSP), University Hospital Centre, Rue de la Corniche 10, 2013 Lausanne, Switzerland
| | - Nick Banatvala
- 2Noncommunicable Diseases and Mental Health Cluster, World Health Organization, Geneva, Switzerland
| |
Collapse
|
13
|
Lim S, Kim PJ, Baek C, Kim TH, Koh YS, Park HJ, Kim HY, Chang K, Chung WS, Seung KB. Antiplatelet Efficacy of Fixed-Dose Aspirin-Clopidogrel Combination in Patients with Stable Coronary Artery Disease Treated with Drug-Eluting Stent Implantation. Clin Drug Investig 2015; 35:833-42. [PMID: 26507618 DOI: 10.1007/s40261-015-0350-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
BACKGROUND AND OBJECTIVES A fixed-dose combination (FDC) of aspirin and clopidogrel bisulfate may improve medication adherence. However, the absence of data on the relative antiplatelet efficacy of FDC and separate dual pills (SDP) of aspirin and clopidogrel in real-world patients with stable coronary artery disease is a major factor retarding clinical introduction of such an FDC. METHODS This was a single-centre, randomized, open-label, parallel-group, non-inferiority trial. Patients who maintained a regimen of separate aspirin and clopidogrel pills for at least 1 year after drug-eluting stent implantation without adverse events were enrolled. Patients were randomly assigned to either the FDC group or the SDP group. Antiplatelet efficacy and tolerability were assessed at baseline and at 4 weeks. RESULTS Of the 93 enrolled patients, 83 (FDC group: n = 42; SDP group: n = 41) completed the study. The difference in the changes in P2Y12 percentage inhibition did not exceed the predetermined value for inferiority [mean difference -1.7; 95 % confidence interval (CI) -6.9 to 4.5, p < 0.001 for non-inferiority]. The changes from baseline to 4 weeks in P2Y12 reaction units (PRU) (mean difference 9.7 PRU, p = 0.46), maximal platelet aggregation (mean difference 2.0 %, p = 0.44) and aspirin reaction units (ARU) (mean difference -2.3 ARU, p = 0.88) did not differ significantly between the treatment groups. The tolerability of the FDC formulation was similar to that of SDP therapy (p = 0.68). CONCLUSION In patients with prior percutaneous coronary intervention, the antiplatelet efficacy of the aspirin/clopidogrel FDC was non-inferior to that of SDP and the tolerability of the two regimens was similar after 4 weeks of treatment.
Collapse
Affiliation(s)
- Sungmin Lim
- Division of Cardiology, Department of Internal Medicine, College of Medicine, Bucheon St. Mary's Hospital, The Catholic University of Korea, Bucheon, Republic of Korea
| | - Pum Joon Kim
- Cardiovascular Center and Cardiology Division, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 137-701, Republic of Korea.
| | - Chunyeong Baek
- Cardiovascular Center and Cardiology Division, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 137-701, Republic of Korea
| | - Tae-Hoon Kim
- Cardiovascular Center and Cardiology Division, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 137-701, Republic of Korea
| | - Yoon Seok Koh
- Cardiovascular Center and Cardiology Division, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 137-701, Republic of Korea
| | - Hun-Jun Park
- Cardiovascular Center and Cardiology Division, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 137-701, Republic of Korea
| | - Hee-Yeol Kim
- Division of Cardiology, Department of Internal Medicine, College of Medicine, Bucheon St. Mary's Hospital, The Catholic University of Korea, Bucheon, Republic of Korea
| | - Kiyuk Chang
- Cardiovascular Center and Cardiology Division, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 137-701, Republic of Korea
| | - Wook Sung Chung
- Cardiovascular Center and Cardiology Division, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 137-701, Republic of Korea
| | - Ki-Bae Seung
- Cardiovascular Center and Cardiology Division, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 137-701, Republic of Korea
| |
Collapse
|
14
|
Wood F, Salam A, Singh K, Day S, Jan S, Prabhakaran D, Rodgers A, Patel A, Thom S, Ward H. Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease. BMJ Open 2015; 5:e008018. [PMID: 26423850 PMCID: PMC4593141 DOI: 10.1136/bmjopen-2015-008018] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
IMPORTANCE The Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE) trial has shown improved adherence with the use of a polypill strategy when compared with usual medications for cardiovascular disease (CVD) prevention. To advance from efficacy to impact, we need a better understanding of why and how such a strategy might be deployed in complex health systems. OBJECTIVE To understand, from the perspective of UMPIRE trial participants and professionals, how and why a polypill strategy improves adherence compared with usual care, why improvement is greater in some subgroups, and to explore the acceptability of a polypill strategy among trial participants and healthcare professionals. DESIGN, SETTING AND PARTICIPANTS A preplanned process evaluation, based on qualitative interviews, was conducted with a subsample of 102 trial participants and 41 healthcare professionals at the end of the UMPIRE trial in India and Europe. RESULTS Most patients contrasted the simplicity of the polypill with usual medications that they found complex and, for many in India, expensive. Patients with low baseline adherence struggled most with complex medication lists, and those without established disease described less motivation to adhere when compared with people who had already been diagnosed with CVD; people in the latter group had already undertaken self-directed measures to adhere to CVD preventive medicines prior to entering the trial. Taking medication was one of many adaptations described by patients; these included dietary changes, stopping smoking and maintaining exercise. Most patients liked the polypill strategy, although some participants and health professionals were concerned that it would provide less tailored therapy for individual needs. CONCLUSIONS Adherence to treatment lists with multiple medications is complex and influenced by several factors. Simplifying medication by using a once-daily polypill is one approach to CVD prevention that may enhance adherence. Prescribers should also consider the wide variety of adjustments that individuals need to make to cope with daily medication.
Collapse
Affiliation(s)
- Frances Wood
- International Centre for Circulatory Health, Imperial College London and Imperial Healthcare NHS Trust, London, UK
| | - Abdul Salam
- George Institute for Global Health, Hyderabad, Telangana, India
- The George Institute for Global Health, University of Sydney, Camperdown, New South Wales, Australia
| | - Kavita Singh
- Centre for Chronic Disease Control and Center for Cardio-metabolic Risk Reduction in South Asia (CARRS), Public Health Foundation of India (PHFI), Gurgaon, Haryana, India
- Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi, India
| | - Sophie Day
- Patient Experience Research Centre, School of Public Health, Imperial College London, London, UK
| | - Stephen Jan
- The George Institute for Global Health, University of Sydney, Camperdown, New South Wales, Australia
| | - Dorairaj Prabhakaran
- Centre for Chronic Disease Control and Center for Cardio-metabolic Risk Reduction in South Asia (CARRS), Public Health Foundation of India (PHFI), Gurgaon, Haryana, India
| | - Anthony Rodgers
- The George Institute for Global Health, University of Sydney, Camperdown, New South Wales, Australia
| | - Anushka Patel
- George Institute for Global Health, Hyderabad, Telangana, India
- The George Institute for Global Health, University of Sydney, Camperdown, New South Wales, Australia
| | - Simon Thom
- International Centre for Circulatory Health, Imperial College London and Imperial Healthcare NHS Trust, London, UK
| | - Helen Ward
- Patient Experience Research Centre, School of Public Health, Imperial College London, London, UK
| |
Collapse
|
15
|
Abstract
Mark Huffman asks what happened to the polypill to reduce cardiovascular risk, explores the promise it still holds, and considers how best to turn promise into reality.
Collapse
Affiliation(s)
- Mark D. Huffman
- Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America
- * E-mail:
| |
Collapse
|
16
|
|
17
|
Liu H, Massi L, Laba TL, Peiris D, Usherwood T, Patel A, Cass A, Eades AM, Redfern J, Hayman N, Howard K, Brien JA, Jan S. Patients’ and Providers’ Perspectives of a Polypill Strategy to Improve Cardiovascular Prevention in Australian Primary Health Care. Circ Cardiovasc Qual Outcomes 2015; 8:301-8. [DOI: 10.1161/circoutcomes.115.001483] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/31/2014] [Accepted: 03/20/2015] [Indexed: 11/16/2022]
Affiliation(s)
- Hueiming Liu
- From The George Institute for Global Health, University of Sydney (H.L., L.M., T.-L.L., D.P., A.P., A.-M.E., J.R., S.J.); Department of General Practice, Western Clinical School, University of Sydney (T.U.); Menzies School of Health Research, Charles Darwin University (A.C.); Inala Indigenous Health Service; School of Public Health, University of Sydney (N.H., K.H.); and Faculty of Pharmacy, University of Sydney (J.-a.B.)
| | - Luciana Massi
- From The George Institute for Global Health, University of Sydney (H.L., L.M., T.-L.L., D.P., A.P., A.-M.E., J.R., S.J.); Department of General Practice, Western Clinical School, University of Sydney (T.U.); Menzies School of Health Research, Charles Darwin University (A.C.); Inala Indigenous Health Service; School of Public Health, University of Sydney (N.H., K.H.); and Faculty of Pharmacy, University of Sydney (J.-a.B.)
| | - Tracey-Lea Laba
- From The George Institute for Global Health, University of Sydney (H.L., L.M., T.-L.L., D.P., A.P., A.-M.E., J.R., S.J.); Department of General Practice, Western Clinical School, University of Sydney (T.U.); Menzies School of Health Research, Charles Darwin University (A.C.); Inala Indigenous Health Service; School of Public Health, University of Sydney (N.H., K.H.); and Faculty of Pharmacy, University of Sydney (J.-a.B.)
| | - David Peiris
- From The George Institute for Global Health, University of Sydney (H.L., L.M., T.-L.L., D.P., A.P., A.-M.E., J.R., S.J.); Department of General Practice, Western Clinical School, University of Sydney (T.U.); Menzies School of Health Research, Charles Darwin University (A.C.); Inala Indigenous Health Service; School of Public Health, University of Sydney (N.H., K.H.); and Faculty of Pharmacy, University of Sydney (J.-a.B.)
| | - Tim Usherwood
- From The George Institute for Global Health, University of Sydney (H.L., L.M., T.-L.L., D.P., A.P., A.-M.E., J.R., S.J.); Department of General Practice, Western Clinical School, University of Sydney (T.U.); Menzies School of Health Research, Charles Darwin University (A.C.); Inala Indigenous Health Service; School of Public Health, University of Sydney (N.H., K.H.); and Faculty of Pharmacy, University of Sydney (J.-a.B.)
| | - Anushka Patel
- From The George Institute for Global Health, University of Sydney (H.L., L.M., T.-L.L., D.P., A.P., A.-M.E., J.R., S.J.); Department of General Practice, Western Clinical School, University of Sydney (T.U.); Menzies School of Health Research, Charles Darwin University (A.C.); Inala Indigenous Health Service; School of Public Health, University of Sydney (N.H., K.H.); and Faculty of Pharmacy, University of Sydney (J.-a.B.)
| | - Alan Cass
- From The George Institute for Global Health, University of Sydney (H.L., L.M., T.-L.L., D.P., A.P., A.-M.E., J.R., S.J.); Department of General Practice, Western Clinical School, University of Sydney (T.U.); Menzies School of Health Research, Charles Darwin University (A.C.); Inala Indigenous Health Service; School of Public Health, University of Sydney (N.H., K.H.); and Faculty of Pharmacy, University of Sydney (J.-a.B.)
| | - Anne-Marie Eades
- From The George Institute for Global Health, University of Sydney (H.L., L.M., T.-L.L., D.P., A.P., A.-M.E., J.R., S.J.); Department of General Practice, Western Clinical School, University of Sydney (T.U.); Menzies School of Health Research, Charles Darwin University (A.C.); Inala Indigenous Health Service; School of Public Health, University of Sydney (N.H., K.H.); and Faculty of Pharmacy, University of Sydney (J.-a.B.)
| | - Julie Redfern
- From The George Institute for Global Health, University of Sydney (H.L., L.M., T.-L.L., D.P., A.P., A.-M.E., J.R., S.J.); Department of General Practice, Western Clinical School, University of Sydney (T.U.); Menzies School of Health Research, Charles Darwin University (A.C.); Inala Indigenous Health Service; School of Public Health, University of Sydney (N.H., K.H.); and Faculty of Pharmacy, University of Sydney (J.-a.B.)
| | - Noel Hayman
- From The George Institute for Global Health, University of Sydney (H.L., L.M., T.-L.L., D.P., A.P., A.-M.E., J.R., S.J.); Department of General Practice, Western Clinical School, University of Sydney (T.U.); Menzies School of Health Research, Charles Darwin University (A.C.); Inala Indigenous Health Service; School of Public Health, University of Sydney (N.H., K.H.); and Faculty of Pharmacy, University of Sydney (J.-a.B.)
| | - Kirsten Howard
- From The George Institute for Global Health, University of Sydney (H.L., L.M., T.-L.L., D.P., A.P., A.-M.E., J.R., S.J.); Department of General Practice, Western Clinical School, University of Sydney (T.U.); Menzies School of Health Research, Charles Darwin University (A.C.); Inala Indigenous Health Service; School of Public Health, University of Sydney (N.H., K.H.); and Faculty of Pharmacy, University of Sydney (J.-a.B.)
| | - Jo-anne Brien
- From The George Institute for Global Health, University of Sydney (H.L., L.M., T.-L.L., D.P., A.P., A.-M.E., J.R., S.J.); Department of General Practice, Western Clinical School, University of Sydney (T.U.); Menzies School of Health Research, Charles Darwin University (A.C.); Inala Indigenous Health Service; School of Public Health, University of Sydney (N.H., K.H.); and Faculty of Pharmacy, University of Sydney (J.-a.B.)
| | - Stephen Jan
- From The George Institute for Global Health, University of Sydney (H.L., L.M., T.-L.L., D.P., A.P., A.-M.E., J.R., S.J.); Department of General Practice, Western Clinical School, University of Sydney (T.U.); Menzies School of Health Research, Charles Darwin University (A.C.); Inala Indigenous Health Service; School of Public Health, University of Sydney (N.H., K.H.); and Faculty of Pharmacy, University of Sydney (J.-a.B.)
| |
Collapse
|
18
|
Sanchis-Gomar F, Fiuza-Luces C, Lucia A. Exercise as the master polypill of the 21st century for the prevention of cardiovascular disease. Int J Cardiol 2014; 181:360-1. [PMID: 25555280 DOI: 10.1016/j.ijcard.2014.12.048] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/18/2014] [Accepted: 12/20/2014] [Indexed: 10/24/2022]
Affiliation(s)
- Fabian Sanchis-Gomar
- Department of Physiology, Faculty of Medicine, University of Valencia, Fundación Investigación Hospital Clínico Universitario/INCLIVA, Spain.
| | - Carmen Fiuza-Luces
- Universidad Europea and Research Institute of Hospital 12 de Octubre ('i+12'), Spain
| | - Alejandro Lucia
- Universidad Europea and Research Institute of Hospital 12 de Octubre ('i+12'), Spain
| |
Collapse
|
19
|
|
20
|
Patanè S. Ebola: is there a hope from treatment with cardiovascular drugs? Int J Cardiol 2014; 177:524-6. [PMID: 25205490 DOI: 10.1016/j.ijcard.2014.08.114] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/14/2014] [Accepted: 08/17/2014] [Indexed: 12/24/2022]
Affiliation(s)
- Salvatore Patanè
- Cardiologia Ospedale San Vincenzo - Taormina (Me) Azienda Sanitaria Provinciale di Messina, Contrada Sirina, 98039 Taormina (Messina), Italy. patane-@libero.it
| |
Collapse
|
21
|
Sanz G, Castellano JM, Fuster V. Polypill: chimera or reality? ACTA ACUST UNITED AC 2014; 67:689-92. [PMID: 25172063 DOI: 10.1016/j.rec.2014.05.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2014] [Accepted: 05/13/2014] [Indexed: 11/29/2022]
Affiliation(s)
- Ginés Sanz
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
| | - José M Castellano
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; Cardiovascular Institute, Mount Sinai School of Medicine, New York, United States
| | - Valentín Fuster
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; Cardiovascular Institute, Mount Sinai School of Medicine, New York, United States
| |
Collapse
|